Search

everythinglearnresearchcommunity

for

Search:↓

One-third of COVID-19 patients had long-term symptoms like hair loss and fatigue, with women, older individuals, blood group B, smokers, and those with more virus exposure at higher risk.

Taking spironolactone doesn't increase the chance of breast cancer coming back.

Genetic variants at 20p11 increase baldness risk in Chinese Han people.

Better patient selection for gastric cancer surgery can reduce complications and improve survival.

More plasma leptin means higher baldness risk in men.

Certain gene variations increase the risk of alopecia areata in Koreans.

Tailoring COVID-19 measures to risk levels in the military improves health and readiness.

AGA patients have higher heart disease risk.

Severe male balding may increase the risk of serious COVID-19, and treatments that reduce androgens or block a specific enzyme might help protect these individuals.

Women with alopecia may have a higher chance of getting thyroid cancer.

Females are more likely than males to experience long-COVID symptoms and heart issues.

High androgen levels in postmenopausal women may suggest an ovarian tumor, and removing it can improve heart and metabolic health.

The book provides updated knowledge on hair disorders and new treatments for hair loss.

Low testosterone increases kidney stone risk in men not on testosterone therapy.

Women with PCOS may have a higher risk of Alzheimer's disease.

Men with melanoma have a higher risk of later being diagnosed with prostate cancer.

Women with severe frontal fibrosing alopecia are more likely to have rosacea.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

Women with PCOS have a higher risk of heart disease.

Women with PCOS are more likely to have depression and anxiety.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Estrogen and androgenic hair increase melanoma risk, especially in European-ancestry individuals.

Isoflavones may help with menopause symptoms but could be risky for women with hormone-sensitive cancers.

Immunization and throat bacteria may increase the risk of a hair loss condition called alopecia areata.

Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.

Finasteride may affect mood and increase suicidal risk.

Lisinopril improves heart health more in men with normal hair than those with early hair loss.

Investing in a longevity megafund can help pension funds reduce longevity risk.